Search research articles
Contact Us
Filters
Showing results (51-60 of 91) with videos related to
Page
of 10
Sort By:
Cancer Research Communications
|
February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications
|
January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Expert Review of Anticancer Therapy
|
December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancer
James Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report
Alexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al.
Molecular Cancer Therapeutics
|
May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
Yves A Millet, Alexander I Spira, Christina S Baik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 91) with videos related to
Sort By:
Page
of 10
Cancer Research Communications
|
February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications
|
January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Expert Review of Anticancer Therapy
|
December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancer
James Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report
Alexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al.
Molecular Cancer Therapeutics
|
May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
Yves A Millet, Alexander I Spira, Christina S Baik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
Page
of 10